 |
|
Underutilization of Lipid-Lowering Therapy in Coronary Artery Disease
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Miller et al1 found relatively low treatment rates of hyperlipidemia among patients with coronary artery disease in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Several large prospective placebo-controlled clinical trials with statins showed benefit in the risk of recurrent coronary events in patients with established coronary heart disease.2-4 In addition to lowering low-density lipoprotein (LDL) cholesterol levels, statin therapy appears to exhibit pleiotropic effects on many components of atherosclerosis, including plaque thrombogenicity, cellular migration, endothelial function, and thrombotic tendency.5 Some studies have demonstrated a high prevalence of modifiable risk factors in coronary heart disease as well as considerable potential to reduce the risk of a further major ischemic event in patients.6-8 In Spain, the PREVESE study6 (secondary prevention of myocardial infarction in Spain) found a very small percentage of lipid-lowering prescription (6.7%) at discharge among 1242 patients with myocardial infarction.
We studied 230 male patients . . . [Full Text of this Article]
RELATED ARTICLE
Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada
Michael Miller, Robert Byington, Donald Hunninghake, Bertram Pitt, Curt D. Furberg, and for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial Investigators
Arch Intern Med. 2000;160(3):343-347.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
Smith et al.
Arch Intern Med 2003;163:688-692.
ABSTRACT
| FULL TEXT
|
